Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20aldesleukinNCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Phase 32021-09-302025-01-30+1218 days
2026-11-20Capecitabine, Gemcitabine, Eribulin mesylateNCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPhase 32025-122027-12-31+760 days
2026-11-20Semaglutide (Ozempic)NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous SemaglutidePhase 2/32027-012027-12+334 days
2026-11-20LetrozoleNCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)Phase 32027-07-012028-02-01+215 days
2026-11-20Ferric derisomaltoseNCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in PregnancyPhase 32026-12-312026-05-31−214 days
2026-11-20Rifaximin SSDNCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPhase 32025-092025-12-23+113 days
2026-11-20Zoledronic acidNCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BonePhase 32027-012027-04+90 days
2026-11-20Oxycodone (Xtampza ER)NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing.Phase 32026-12-312027-03-31+90 days
2026-11-20GoserelinNCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Phase 32035-102035-12+61 days
2026-11-20Semaglutide (Wegovy)NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsPhase 32031-022031-03+28 days
2026-11-19AnakinraNCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenPhase 32025-06-012027-10-01+852 days
2026-11-19tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), BictegravirNCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedPhase 2/32028-012026-11-03−424 days
2026-11-19PovetaciceptNCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase 2/32028-12-292029-06-27+180 days
2026-11-19PF-08634404, PembrolizumabNCT06980272SSGJ-707 in Advanced Non-Small Cell Lung CancerPhase 32026-07-302026-02-01−179 days
2026-11-19AND017NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPhase 32026-10-302027-02-20+113 days
2026-11-19AND017NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Phase 32026-12-012027-03-01+90 days
2026-11-19Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, CarfilzomibNCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 32028-10-312028-11-30+30 days
2026-11-19tilrekimigNCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimePhase 32034-05-122034-04-21−21 days
2026-11-19Depemokimab, MepolizumabNCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Phase 32026-09-292026-10-06+7 days
2026-11-18tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, BictegravirNCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityPhase 32026-06-052027-12-05+548 days
2026-11-18INCB123667NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 32028-11-152027-10-12−400 days
2026-11-18Gemcitabine, AtezolizumabNCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerPhase 32027-06-012026-07-23−313 days
2026-11-18Methotrexate, etanerceptNCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiSPhase 32025-02-282025-10-31+245 days
2026-11-18faricimabNCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRPhase 32031-082032-02+184 days
2026-11-18viloxazineNCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Phase 32026-092026-12+91 days
2026-11-18DepemokimabNCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPhase 32029-04-302029-04-02−28 days
2026-11-18TemozolomideNCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPhase 32035-11-022035-11-30+28 days
2026-11-18InclisiranNCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesPhase 32027-02-112027-01-16−26 days
2026-11-18TafolecimabNCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPhase 32026-09-062026-08-26−11 days
2026-11-17zasocitinibNCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPhase 32033-01-242034-07-03+525 days
2026-11-17Iparomlimab and tuvonralimabNCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerPhase 32032-08-312032-12-31+122 days
2026-11-17HRG2010NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsPhase 32025-10-092026-01-29+112 days
2026-11-17DostarlimabNCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerPhase 32029-12-122030-03-13+91 days
2026-11-17Daraxonrasib, Nab-paclitaxel, GemcitabineNCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 32028-062028-04−61 days
2026-11-14Oxycodone (Xtampza ER)NCT04659317Opioid-Free OrthopaedicsPhase 32028-122026-07-20−865 days
2026-11-14Rosuvastatin, LaroprovstatNCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/32025-07-032027-02-22+599 days
2026-11-14Omega-3-acid ethyl esters (Lovaza)NCT02178410VITAL Rhythm StudyPhase 32026-102027-10+365 days
2026-11-14upadacitinibNCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPhase 32028-032028-08+153 days
2026-11-14Trastuzumab Emtansine, InavolisibNCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 32026-12-312027-05-03+123 days
2026-11-14BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32026-11-142026-08-13−93 days
2026-11-14ADSTEMNCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPhase 32029-062029-09+92 days
2026-11-14SuzetrigineNCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic SurgeryPhase 32026-12-312027-03-31+90 days
2026-11-14BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-11-142026-08-25−81 days
2026-11-14maralixibatNCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Phase 32026-102026-07-29−64 days
2026-11-14Bempedoic acidNCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidPhase 32025-102025-08-05−57 days
2026-11-13MethylprednisoloneNCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical TrialPhase 32027-01-312029-01-31+731 days
2026-11-13Naloxone (Narcan)NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentPhase 32026-08-312026-01-30−213 days
2026-11-13Docetaxel, OSE2101NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 32027-12-152028-05-01+138 days
2026-11-13VosoritideNCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 32026-08-012026-04-23−100 days
2026-11-13VadadustatNCT06520826Vafseo Outcomes In-Center ExperiencePhase 32026-06-302026-09-10+72 days
2026-11-13EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32026-12-302027-02-26+58 days
2026-11-13barzolvolimabNCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Phase 32026-102026-08-04−58 days
2026-11-13barzolvolimabNCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPhase 32026-102026-08-12−50 days
2026-11-13BofanglutideNCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsPhase 32026-052026-03-26−36 days
2026-11-13GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32029-01-012029-01-31+30 days
2026-11-13Odronextamab, RituximabNCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 32028-02-072028-02-29+22 days
2026-11-13Ruxolitinib (Opzelura)NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Phase 32026-10-092026-10-29+20 days
2026-11-13Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, CarfilzomibNCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 32026-08-302026-08-26−4 days
2026-11-13setmelanotideNCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPhase 32025-12-222025-12-19−3 days
2026-11-11MethotrexateNCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisPhase 2/32026-072031-11+1949 days
2026-11-11PelacarsenNCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 32028-08-242026-10-15−679 days
2026-11-11BofanglutideNCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPhase 32027-092026-09-22−344 days
2026-11-11Fianlimab, Cemiplimab, PembrolizumabNCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPhase 32026-07-272027-01-15+172 days
2026-11-11Bofanglutide, Semaglutide (Ozempic)NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusPhase 32026-12-112026-09-18−84 days
2026-11-11Tirzepatide (Zepbound)NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialPhase 2/32027-01-012026-10-10−83 days
2026-11-11Ranibizumab, BevacizumabNCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)Phase 32026-072026-05-28−34 days
2026-11-11retatrutideNCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPhase 32027-072027-06−30 days
2026-11-11AfliberceptNCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Phase 32026-102026-09-09−22 days
2026-11-11Cabotegravir/rilpivirine (Cabenuva)NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPhase 32029-09-042029-08-13−22 days
2026-11-11BofanglutideNCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExercisePhase 32026-08-072026-07-30−8 days
2026-11-11metreleptinNCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPhase 32026-07-212026-07-14−7 days
2026-11-11zenagamtide, Semaglutide (Ozempic)NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 32028-12-122028-12-19+7 days
2026-11-11rilzabrutinibNCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanPhase 32026-11-302026-11-25−5 days
2026-11-10IncobotulinumtoxinA (Xeomin)NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Phase 32011-092013-11-12+803 days
2026-11-10remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-292031-10-15−14 days
2026-11-10Ruxolitinib (Opzelura)NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Phase 32026-10-092026-10-01−8 days
2026-11-10tralokinumabNCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisPhase 32026-10-202026-10-16−4 days
2026-11-08BosentanNCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION PatientsPhase 32023-122027-02+1158 days
2026-11-08Tarlatamab, DurvalumabNCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabPhase 32027-07-052030-04-02+1002 days
2026-11-08Olanzapine (Zyprexa)NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control TrialPhase 32026-11-012027-11-01+365 days
2026-11-08Rituximab, ObinutuzumabNCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic SyndromePhase 2/32027-10-182027-06-30−110 days
2026-11-08PertuzumabNCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialPhase 32026-12-312027-03-28+87 days
2026-11-08BevacizumabNCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerPhase 32030-06-182030-06-28+10 days
2026-11-07Famitinib, CamrelizumabNCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)Phase 32025-08-302026-05-30+273 days
2026-11-07DostarlimabNCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LinePhase 32026-042026-10-01+183 days
2026-11-07FampridineNCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 32026-122027-05+151 days
2026-11-07ZiltivekimabNCT06263244Specifying the Anti-inflammatory Effects of ZiltivekimabPhase 32026-09-042026-10-30+56 days
2026-11-07TrontinemabNCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePhase 32032-09-032032-07-30−35 days
2026-11-07Cemdisiran, Pozelimab, Eculizumab, RavulizumabNCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentPhase 32026-10-122026-09-28−14 days
2026-11-06baricitinibNCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Phase 32022-042025-07-30+1216 days
2026-11-06Quetiapine (Seroquel), Clozapine, valproate, EsketamineNCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment FailurePhase 32028-06-302026-06-24−737 days
2026-11-06DexamethasoneNCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase 32028-08-022028-11-30+120 days
2026-11-06Aflibercept, Tabirafusp tedromer, Tarcocimab tedromerNCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPhase 32026-082026-09-02+32 days
2026-11-06Furosemide (subcutaneous, SQ Innovation)NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart FailurePhase 32028-08-012028-09-01+31 days
2026-11-06maridebart cafraglutide, Semaglutide (Ozempic)NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPhase 32028-09-042028-09-06+2 days
2026-11-05Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinibNCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPhase 32026-022028-06+851 days
2026-11-05Sintilimab, Nab-paclitaxelNCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)Phase 32025-11-112026-11-30+384 days
2026-11-05Sotagliflozin (Inpefa)NCT07211802CKM For Safe Use of SGLT2i in Type 1 DiabetesPhase 32030-07-312031-07-31+365 days
2026-11-05metforminNCT06452498Preeclampsia Intervention NetherlandsPhase 32028-042029-03-19+352 days
2026-11-05CapecitabineNCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerPhase 2/32026-072025-07-31−335 days
2026-11-05Rituximab, NivolumabNCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 32026-12-312027-06-30+181 days
2026-11-05Monalizumab, Oleclumab, DurvalumabNCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPhase 32026-09-302027-01-08+100 days
2026-11-05DapagliflozinNCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)Phase 32026-082026-10-30+90 days
2026-11-05Albuterol sulfate (Proventil HFA), albuterol (Armstrong Albuterol HFA), fluticasone propionateNCT06052267A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsPhase 32026-10-312026-12-31+61 days
2026-11-05fluticasone propionateNCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 32026-11-022026-10-26−7 days
2026-11-05Risdiplam (Evrysdi)NCT05115110A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyPhase 2/32026-10-282026-11-02+5 days
2026-11-04metforminNCT04177303Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin TreatmentPhase 32022-11-292024-12-31+763 days
2026-11-04jaktinibNCT05676242A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisPhase 32024-122026-03-12+466 days
2026-11-04jaktinibNCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisPhase 32026-062025-08-05−300 days
2026-11-04Tobevibart (VIR-3434)NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPhase 32026-12-312026-09-30−92 days
2026-11-04dupilumabNCT02612454Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Phase 32026-10-072026-10-09+2 days
2026-11-03Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab GovitecanNCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerPhase 32030-08-152026-03-05−1624 days
2026-11-03Entrectinib, Alectinib, DurvalumabNCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 32030-06-162027-01-19−1244 days
2026-11-03FurmonertinibNCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Phase 32025-08-152026-10-06+417 days
2026-11-03LanifibranorNCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Phase 32027-09-302026-09-29−366 days
2026-11-03HydroxychloroquineNCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for PreeclampsiaPhase 32026-12-312027-12-31+365 days
2026-11-03DexamethasoneNCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhagePhase 32024-122024-09-09−83 days
2026-11-01RituximabNCT03560011Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic SyndromePhase 2/32021-01-072022-11-04+666 days
2026-11-01Bemdaneprocel (MSK-DA01)NCT06944522A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePhase 32027-032028-10+580 days
2026-11-01Nab-paclitaxelNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-11-01BevacizumabNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-11-01PumitamigNCT06616532PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerPhase 32027-01-252027-05+96 days
2026-11-01Docetaxel, Gemcitabine, Risvutatug rezetecanNCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailurePhase 32026-08-312026-06-17−75 days
2026-11-01N-acetylcysteine, metforminNCT06836128The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome PatientsPhase 32026-02-012026-03-30+57 days
2026-11-01Risvutatug rezetecanNCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerPhase 32026-09-302026-08-20−41 days
2026-11-01DocetaxelNCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 32031-06-172031-05-30−18 days
2026-11-01BevacizumabNCT07816666Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPhase 32028-09-262028-09-29+3 days
2026-11-01Goserelin, Methylprednisolone, DocetaxelNCT04787744Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPhase 2/32026-09-302026-10-02+2 days
2026-10-31Vigabatrin (Sabril)NCT04987463Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsPhase 2/32026-032028-12+1006 days
2026-10-31VericiguatNCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Phase 2/32032-04-152029-08-20−969 days
2026-10-31Trastuzumab DeruxtecanNCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingPhase 32032-03-232030-02-26−756 days
2026-10-31Trastuzumab pamirtecan, Trastuzumab EmtansineNCT06265428A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerPhase 32026-022027-12+668 days
2026-10-31metforminNCT05468554Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid CancerPhase 32026-04-302028-01-31+641 days
2026-10-31SintilimabNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-31TadalafilNCT05195775Tadalafil as Adjuvant Therapy for DMDPhase 2/32025-09-052024-04-16−507 days
2026-10-31MethylprednisoloneNCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICUPhase 32025-10-252024-11-24−335 days
2026-10-31MevrometostatNCT06629779A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Phase 32026-12-022027-09-30+302 days
2026-10-31tocilizumab, MethotrexateNCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled TrialPhase 32027-012026-03-27−280 days
2026-10-31Dexamethasone, Rituximab, MethotrexateNCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 32027-03-012027-11-01+245 days
2026-10-31Rifaximin (Xifaxan)NCT07522255Rifaximin Treatment in Bloating Predominant Functional Bowel DisordersPhase 32027-102028-06+244 days
2026-10-31TricaprilinNCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) StudyPhase 32029-062030-01+214 days
2026-10-31DocetaxelNCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 32026-11-112027-05-03+173 days
2026-10-31Adebrelimab, BevacizumabNCT07691762A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaPhase 32031-042031-09+153 days
2026-10-31Rituximab, VenetoclaxNCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasPhase 2/32028-04-012028-08-13+134 days
2026-10-31TelikibartNCT06516302A Study of GR1802 in Participants With Chronic Sinusitis With Nasal PolypsPhase 32026-032026-06-12+103 days
2026-10-31Sacituzumab TirumotecanNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-31Mevrometostat, DocetaxelNCT06551324A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Phase 32026-12-282027-02-28+62 days
2026-10-31RademikibartNCT06488755SIM0718 Treatment of Asthma Clinical StudyPhase 32027-02-282026-12-31−59 days
2026-10-31RanibizumabNCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPhase 2/32027-03-012027-01-11−49 days
2026-10-31AmmoxetineNCT06827431The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionPhase 32026-06-302026-07-14+14 days
2026-10-29Trastuzumab DeruxtecanNCT06174987A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Phase 32026-08-032028-02-17+563 days
2026-10-29hepalatideNCT07309380Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DPhase 32027-062028-06+366 days
2026-10-29GabapentinNCT04724252Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in ChildrenPhase 2/32026-12-312027-12-31+365 days
2026-10-29Ferric derisomaltoseNCT05407987Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)Phase 32026-12-302027-12-30+365 days
2026-10-29PembrolizumabNCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Phase 2/32028-082029-04+243 days
2026-10-29lebrikizumabNCT06339008A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Phase 32026-092026-10-22+51 days
2026-10-29LenbelintideNCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightPhase 32028-08-082028-08-09+1 day
2026-10-28survodutideNCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 32028-06-252029-11-06+499 days
2026-10-28Ordastobart, PembrolizumabNCT06295731Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Phase 2/32029-052029-12+214 days
2026-10-27Staccato AlprazolamNCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPhase 32026-10-312027-03-29+149 days
2026-10-27Cabotegravir/rilpivirine (Cabenuva)NCT06507059Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting AntiretroviralsPhase 32025-07-012025-08-06+36 days
2026-10-27DapagliflozinNCT06783166Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart FailurePhase 2/32025-07-012025-07-04+3 days
2026-10-26EverolimusNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-26IpilimumabNCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPhase 32028-01-252028-03-01+36 days
2026-10-26RavulizumabNCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)Phase 32027-08-172027-08-24+7 days
2026-10-24PembrolizumabNCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Phase 32026-07-312028-07-31+731 days
2026-10-24Rimegepant (Nurtec ODT)NCT06616194A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigrainePhase 32028-08-192030-02-26+556 days
2026-10-24metforminNCT04578652Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin ResistancePhase 32026-092027-02+153 days
2026-10-24TolvaptanNCT04782258A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Phase 32028-07-312028-12-28+150 days
2026-10-24Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox)NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerPhase 32026-11-302027-01-30+61 days
2026-10-24AficamtenNCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyPhase 32026-08-312026-07-14−48 days
2026-10-24pemetrexedNCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPhase 32026-10-312026-09-22−39 days
2026-10-23GemcitabineNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-10-23GemcitabineNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-10-23Pertuzumab, Trastuzumab DeruxtecanNCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 32026-11-112027-05-03+173 days
2026-10-23HB0017NCT06477237Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPhase 32024-082024-11-15+106 days
2026-10-23DocetaxelNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-22Capecitabine, Eribulin mesylate, Sacituzumab Tirumotecan, Nab-paclitaxelNCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerPhase 32026-072027-04+274 days
2026-10-22Dexamethasone, CT-P44, Lenalidomide, DaratumumabNCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaPhase 32027-11-152027-03-08−252 days
2026-10-22AZD0120, LenalidomideNCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Phase 32028-10-112028-11-02+22 days
2026-10-21N-acetylcysteineNCT03900988Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and PneumoniaPhase 32025-10-312027-10-31+730 days
2026-10-21Fruquintinib, AxitinibNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-21SHR-1918NCT07349615A Study of SHR-1918 In Participants With HypertriglyceridemiaPhase 32027-112027-03−245 days
2026-10-20MethotrexateNCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)Phase 32029-122026-08-06−1213 days
2026-10-20Cetuximab, PembrolizumabNCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 32029-11-302032-12-25+1121 days
2026-10-20Gemcitabine, pemetrexed, PembrolizumabNCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 32027-01-312030-01-31+1096 days
2026-10-20metforminNCT06763328Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing ChemotherapyPhase 32029-06-162031-06-16+730 days
2026-10-20AfrezzaNCT06535789Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesPhase 2/32025-072026-09-05+431 days
2026-10-20AfliberceptNCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPhase 32028-112027-11−366 days
2026-10-20Dexamethasone, Etentamig, Lenalidomide, DaratumumabNCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantPhase 2/32040-092041-03+181 days
2026-10-20tanruprubartNCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)Phase 32026-12-312027-05-31+151 days
2026-10-20tradipitantNCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisPhase 32025-122026-03-30+119 days
2026-10-20PembrolizumabNCT03244384Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerPhase 32026-10-312027-01-01+62 days
2026-10-20Nivolumab, CabozantinibNCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPhase 32028-01-252028-03-01+36 days
2026-10-17upadacitinibNCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseasePhase 32027-062031-01+1310 days
2026-10-17BenralizumabNCT06750289Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentPhase 32028-11-032026-09-21−774 days
2026-10-17DapagliflozinNCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsPhase 32026-092027-09+365 days
2026-10-17dupilumab, upadacitinibNCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisPhase 32030-072029-11−242 days
2026-10-17Eptinezumab (Vyepti)NCT04965675A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigrainePhase 32026-09-052027-03-26+202 days
2026-10-17dupilumab, upadacitinibNCT06389136A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabPhase 32026-082026-11+92 days
2026-10-17lamivudine (Epivir-HBV), DolutegravirNCT04022967ANRS 12372 MODERATO StudyPhase 32025-02-052024-12-30−37 days
2026-10-17deucravacitinibNCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsPhase 32024-09-052024-10-10+35 days
2026-10-17CenobamateNCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPhase 32026-112026-10-02−30 days
2026-10-17nemolizumabNCT07762833Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisPhase 32027-09-282027-10-28+30 days
2026-10-17BaxdrostatNCT07007793Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.Phase 32027-08-132027-07-27−17 days
2026-10-16Dapagliflozin, metforminNCT05601336Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary SyndromePhase 32023-07-302026-05-01+1006 days
2026-10-16BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32025-12-292026-11-14+320 days
2026-10-16BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-03-202026-11-14+239 days
2026-10-16PembrolizumabNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-10-16Capecitabine, Fulvestrant, Eribulin mesylate, Alpelisib (BYL719)NCT05063786Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)Phase 32026-062025-12-23−160 days
2026-10-16BGM0504NCT06704581A Study of BGM0504 Injection in Participants With Obesity or OverweightPhase 32025-11-272026-03-17+110 days
2026-10-16pemetrexed, Datopotamab Deruxtecan, OsimertinibNCT06417814A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 32026-09-302027-01-11+103 days
2026-10-16TelitaciceptNCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Phase 32027-052027-03−61 days
2026-10-16Fulvestrant, CapivasertibNCT06764186A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainPhase 32027-12-312027-11-30−31 days
2026-10-16SaruparibNCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 32031-06-172031-05-30−18 days
2026-10-15Docetaxel, GoserelinNCT03678025Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 32028-04-012033-04-01+1826 days
2026-10-15CapecitabineNCT04495088Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal CancerPhase 32030-082026-07-31−1462 days
2026-10-15SomatropinNCT06103513Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in ChildrenPhase 32025-06-102028-01-05+939 days
2026-10-15Apatinib, CamrelizumabNCT05062837Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCPhase 2/32024-09-302026-12-30+821 days
2026-10-15GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32026-12-012029-01-01+762 days
2026-10-15GemcitabineNCT04574960Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)Phase 32026-122027-12+365 days
2026-10-15Nivolumab, AtezolizumabNCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Phase 32028-04-062027-08-17−233 days
2026-10-15Trastuzumab EmtansineNCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Phase 32027-10-312028-06-15+228 days
2026-10-15EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32027-08-042026-12-30−217 days
2026-10-15IncobotulinumtoxinA (Xeomin)NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePhase 32027-102027-03−214 days
2026-10-15PF-08634404NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPhase 2/32032-01-152031-07-22−177 days
2026-10-15Pumitamig, AtezolizumabNCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerPhase 32028-122029-04+121 days
2026-10-15Capsaicin (Qutenza)NCT06023706Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.Phase 32027-01-082027-05-08+120 days
2026-10-15Aripiprazole (Abilify), Cariprazine (QLM1016)NCT06799559Study on the Efficacy and Safety of QLM1016 in SchizophreniaPhase 32026-072026-10-23+114 days
2026-10-15Montelukast (Singulair)NCT06113640Montelukast in Parkinson DiseasePhase 2/32026-11-202026-08-20−92 days
2026-10-15VenetoclaxNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-15Calcipotriene/Betamethasone Dipropionate CreamNCT07357831A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsPhase 32026-10-102026-08-06−65 days
2026-10-15AR1001NCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)Phase 32026-052026-06-29+59 days
2026-10-15PelacarsenNCT07625306Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLPhase 32028-12-072029-01-22+46 days
2026-10-15Haloperidol, Olanzapine (Zyprexa)NCT07246187Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency DepartmentPhase 32026-10-312026-09-25−36 days
2026-10-15Capecitabine, Datopotamab Deruxtecan, Durvalumab, PembrolizumabNCT05629585A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Phase 32027-09-202027-09-01−19 days
2026-10-15Ruxolitinib (Jakafi), BomedemstatNCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Phase 32027-07-302027-07-14−16 days
2026-10-15OmalizumabNCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksPhase 32028-06-022028-05-24−9 days
2026-10-15remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-242031-10-29+5 days
2026-10-15remibrutinibNCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 32029-07-242029-07-25+1 day
2026-10-14Denosumab (Prolia)NCT04547348The DENOCHARCOT TrialPhase 32025-10-012030-08-01+1765 days
2026-10-14Cemiplimab, Nivolumab, Pembrolizumab, AtezolizumabNCT05317858Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsPhase 32027-06-012031-06-01+1461 days
2026-10-14diazoxide cholineNCT05701774Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromePhase 32028-062026-01-12−871 days
2026-10-14LetrozoleNCT05316935GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia PatientsPhase 2/32026-03-302028-03-30+731 days
2026-10-14LetrozoleNCT06379113GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer PatientsPhase 2/32026-03-302028-03-30+731 days
2026-10-14DocetaxelNCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 32031-042030-03−396 days
2026-10-14AficamtenNCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMPhase 2/32028-032029-03+365 days
2026-10-14NivolumabNCT06022861A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaPhase 32025-062026-05-17+350 days
2026-10-14BGM0504, Semaglutide (Ozempic)NCT07064486A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPhase 32026-07-312027-04-30+273 days
2026-10-14DocetaxelNCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/32026-10-312027-06-30+242 days
2026-10-14NivolumabNCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPhase 2/32032-01-152031-07-22−177 days
2026-10-14Atezolizumab, BevacizumabNCT05482516Evaluating Novel Therapies in ctDNA Positive GI CancersPhase 32026-122026-08-20−103 days
2026-10-14AzetukalnerNCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderPhase 32026-082026-10+61 days
2026-10-14onabotulinumtoxinANCT05878951Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder SymptomsPhase 2/32026-09-012026-10+30 days
2026-10-14DepemokimabNCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialPhase 32027-11-242027-10-29−26 days
2026-10-14DocetaxelNCT05132075Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerPhase 32026-08-252026-09-03+9 days
2026-10-14remibrutinibNCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksPhase 32028-06-022028-05-24−9 days
2026-10-14EsomeprazoleNCT05267613Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.Phase 32026-08-142026-08-10−4 days
2026-10-14ustekinumabNCT05299931An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation StudyPhase 32026-062026-05-29−3 days
2026-10-13ObinutuzumabNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-12AcalabrutinibNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-10pemetrexed, Volrustomig, PembrolizumabNCT05984277A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Phase 32029-02-282026-08-17−926 days
2026-10-10AlixorextonNCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPhase 2/32028-062030-06+730 days
2026-10-10Sacubitril/valsartanNCT06693674Effect of Sacubitril-Valsartan on Cardiac Structure and FunctionPhase 32026-122028-08+609 days
2026-10-10garetosmabNCT07559513A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Phase 32028-12-102030-07-08+575 days
2026-10-10sonelokimabNCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPhase 32027-02-042026-05-28−252 days
2026-10-10ZimislecelNCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPhase 32027-06-302027-12-31+184 days
2026-10-10metforminNCT02275845Medico-GDM Trial - Metformine to Prevent Gestational Diabetes MellitusPhase 32016-092017-03-03+183 days
2026-10-10sonelokimab, risankizumabNCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 32027-01-152027-01-04−11 days
2026-10-09AzetukalnerNCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Phase 32026-102028-01+457 days
2026-10-09Bevacizumab, AtezolizumabNCT03148418A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Phase 32026-12-312026-11-30−31 days
2026-10-07LecanemabNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePhase 32029-06-302026-12-31−912 days
2026-10-07VildagliptinNCT02849899Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant PeriodPhase 32024-072026-06-05+704 days
2026-10-07VonaprumentNCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Phase 32026-10-312027-07-31+273 days
2026-10-07fluticasone propionateNCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 32026-09-192026-11-02+44 days
2026-10-07ElismetrepNCT07816367A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 32027-092027-10+30 days
2026-10-07maridebart cafraglutideNCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 32027-09-032027-08-20−14 days
2026-10-07tilrekimigNCT07772921A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaPhase 32029-06-122029-06-01−11 days
2026-10-07tilrekimig, dupilumabNCT07783425A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPhase 32028-08-292028-09-08+10 days
2026-10-06Telisotuzumab Adizutecan, pemetrexed, OsimertinibNCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/32031-122036-11+1797 days
2026-10-06AbemaciclibNCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaPhase 32025-122027-12+730 days
2026-10-06FinerenoneNCT06058585The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectPhase 32028-08-302029-12-31+488 days
2026-10-06Telisotuzumab Adizutecan, RamucirumabNCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 32031-042030-03−396 days
2026-10-06Calderasib, PembrolizumabNCT06345729A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 32029-02-192028-01-24−392 days
2026-10-06Haloperidol, Olanzapine (Zyprexa)NCT04833023HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled TrialPhase 32024-122025-09-25+298 days
2026-10-06DepemokimabNCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)Phase 32029-08-212028-12-13−251 days
2026-10-06DepemokimabNCT06959095Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationPhase 32029-08-202028-12-13−250 days
2026-10-06EmestedastatNCT06125951Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseasePhase 2/32026-102026-09-22−9 days
2026-10-03Exemestane, Letrozole, Fulvestrant, Everolimus, AnastrozoleNCT07024173A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerPhase 32026-122027-08+243 days
2026-10-03Giredestrant, Docetaxel, PertuzumabNCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Phase 32027-12-312028-06-15+167 days
2026-10-03IsatuximabNCT07732712Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsPhase 2/32028-08-012028-12-31+152 days
2026-10-03afimkibartNCT06588855A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisPhase 32027-01-302026-10-29−93 days
2026-10-03AnifrolumabNCT07691970Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPhase 32032-12-312032-12-30−1 day
2026-10-02DapagliflozinNCT06759077Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of LifePhase 32024-12-282026-03-28+455 days
2026-10-02TretinoinNCT06447480Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color PatientsPhase 32026-09-012027-09-01+365 days
2026-10-02Ipilimumab, NivolumabNCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Phase 32030-122031-12+365 days
2026-10-02elecoglipronNCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPhase 32027-06-042028-04-06+307 days
2026-10-02MepolizumabNCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)Phase 32025-112025-02-21−253 days
2026-10-02etanerceptNCT06596772A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisPhase 32025-102026-02-20+142 days
2026-10-01Eptinezumab (Vyepti)NCT06428838Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency ContextPhase 32025-12-302028-03+792 days

Showing the newest 300 of 521 moves. Each drug page lists every registry date for its own studies.

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.